MHIP stock forecast, quote, news & analysis

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

The investment seeks to generate returns (before Fund fees and expenses) that over time exceed the healthcare costs for an individual utilizing an employer-provided health plan in the United States (“U.S. Healthcare Cost Inflation”). The common stocks in which the fund primarily invests are those issued by companies in the U.S. healthcare sector and sectors that comprise the supply chain for the U.S. healthcare sector, and include companies of all capitalization sizes. Milliman determines the common stock portfolio weight by implementing a factor approach. The fund is non-diversified.

The average market capitalization across the Milliman Healthcare Inflation Plus ETF (MHIP) ETF is 122.34B. The market cap for tickers in the group ranges from 9.9B to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is MOH at 9.9B.

The average weekly price growth across all stocks in the Milliman Healthcare Inflation Plus ETF (MHIP) ETF was 20%. For the same ETF, the average monthly price growth was 64%, and the average quarterly price growth was 340%. MRNA experienced the highest price growth at 15%, while SMMT experienced the biggest fall at -16%.

The average weekly volume growth across all stocks in the Milliman Healthcare Inflation Plus ETF (MHIP) ETF was 8%. For the same stocks of the ETF, the average monthly volume growth was 41% and the average quarterly volume growth was -14%